Table 1.
AP parameters under FCCP (1 μmol/L) treatment (n = 18 for each).
| dV/dtmax (V/s) | RP (mV) | APA (mV) | APD20 (ms) | APD50 (ms) | APD90 (ms) | |
|---|---|---|---|---|---|---|
| Control | 126:6 ± 10:0 | –77.6 ± 0.5 | 107.2 ± 1.3 | 86.4 ± 2.0 | 130.7 ± 1.7 | 159.3 ± 1.6 |
| FCCP↑ | 88.4 ± 7.7* | –72.6 ± 1.0* | 94.0 ± 3.3* | 90.4 ± 2.0* | 142.3 ± 2.5* | 178.0 ± 2.7* |
| FCCP 2.5′ | 65.4 ± 6.9* | –69.2 ± 1.2* | 88.7 ± 3.3* | 60.8 ± 3.3* | 95.2 ± 5.3* | 125.1 ± 6.2* |
| FCCP 5′ | 70.6 ± 9.7* | –69.0 ± 1.4* | 75.0 ± 6.1* | 29.6 ± 4.3* | 46.8 ± 6.3* | 73.7 ± 6.6* |
Control – Tyrode solution containing glibenclamide (10 μmol/L) and blebbistatin (20 μmol/L), FCCP↑, FCCP 2.5′, and FCCP 5′, FCCP effects at the maximal prolongation of APD, at 2.5 min, and at 5 min, respectively; dV/dtmax, the maximal value of the first time derivative of the AP upstroke; RP, resting membrane potential; APA, AP amplitude; APD20, APD50, and APD90, APD at 20, 50, and 90% of repolarization, respectively. FCCP↑, the time of the maximal prolongation of AP upon FCCP action. Note the averaged depth of microelectrode insertion was 1.78 ± 0.15 mm from the epicardium. Statistical analysis was performed using ANOVA. ∗p < 0.05 vs. control.